Nascent Biotech Inc. Quarterly Debt-to-equity in % from Q3 2015 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Nascent Biotech Inc. quarterly Debt-to-equity history and growth rate from Q3 2015 to Q2 2024.
  • Nascent Biotech Inc. Debt-to-equity for the quarter ending June 30, 2024 was -430 %, a 200% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 -430 -287 -200% Jun 30, 2024
Q1 2024 -275 -133 -93.9% Mar 31, 2024
Q4 2023 -186 -42.1 -29.2% Dec 31, 2023
Q3 2023 -152 +7.44 +4.65% Sep 30, 2023
Q2 2023 -143 -11.3 -8.59% Jun 30, 2023
Q1 2023 -142 -0.43 -0.3% Mar 31, 2023
Q4 2022 -144 +23.2 +13.9% Dec 31, 2022
Q3 2022 -160 -26.2 -19.6% Sep 30, 2022
Q2 2022 -132 +3.99 +2.94% Jun 30, 2022
Q1 2022 -141 -17.7 -14.3% Mar 31, 2022
Q4 2021 -167 -64.5 -62.8% Dec 31, 2021
Q3 2021 -134 -31.9 -31.4% Sep 30, 2021
Q2 2021 -136 -35.6 -35.6% Jun 30, 2021
Q1 2021 -124 -23.3 -23.2% Mar 31, 2021
Q4 2020 -103 +2.26 +2.15% Dec 31, 2020
Q3 2020 -102 +8.52 +7.73% Sep 30, 2020
Q2 2020 -100 +17.5 +14.8% Jun 30, 2020
Q1 2020 -100 +22.9 +18.6% Mar 31, 2020
Q4 2019 -105 +24.2 +18.7% Dec 31, 2019
Q3 2019 -110 +655 +85.6% Sep 30, 2019
Q2 2019 -118 -180 -290% Jun 30, 2019
Q1 2019 -123 -152 -525% Mar 31, 2019
Q4 2018 -129 -150 -728% Dec 31, 2018
Q3 2018 -765 -786 -3669% Sep 30, 2018
Q2 2018 62 +40.4 +187% Jun 30, 2018
Q1 2018 29 -87.8 -75.1% Mar 31, 2018
Q4 2017 20.6 +1.13K Dec 31, 2017
Q3 2017 21.4 +347 Sep 30, 2017
Q2 2017 21.6 +224 Jun 30, 2017
Q1 2017 117 +289 Mar 31, 2017
Q4 2016 -1.11K -954 -605% Dec 31, 2016
Q3 2016 -326 -182 -127% Sep 30, 2016
Q2 2016 -203 Jun 30, 2016
Q1 2016 -173 Mar 31, 2016
Q4 2015 -158 Dec 31, 2015
Q3 2015 -144 Sep 30, 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.